Eveotec, Indivumed partner on novel lung cancer therapies

January 24, 2020 -- Evotec and Indivumed announced on January 23 a partnership to collaborate on drug discovery and development of novel therapies for non-small cell lung cancer. The goal of the collaboration is to provide highly effective precision medicine treatments for patients.

Evotec will bring its proprietary bioinformatics analysis platform called PanHunter to the table and also several small-molecule and antibody discovery platforms. Indivumed will provide access to its multiomics cancer database, IndivuType, along with advanced analytics and artificial intelligence capabilities. High-quality oncology patient data will complement advanced multiomics data analysis for the development of small-molecule and antibody therapies.

This agreement is a continuation of a previous joint drug discovery program focused on colorectal cancer started in April 2019.

HighRes, Novo Nordisk work on robotic drug discovery
Life science robotics company HighRes Biosolutions and global healthcare company Novo Nordisk plan to design a robotic platform for high-throughput biologics...
Evotec, Bayer partner for drug discovery in women's health
Evotec and Bayer announced on January 9 the expansion of their partnership in women's health with a new five-year, multitarget collaboration with participation...
Merck announces new drug development collaboration
Merck announced on January 6 that it has entered into an exclusive worldwide research collaboration and license agreement with Taiho Pharmaceutical and...

Copyright © 2020 scienceboard.net

Microscopy and Microanalysis Meeting
July 31 - August 4
Portland, Oregon United States
Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter